- Home
- LFST vs DNLI Comparison
LFST vs DNLI Comparison
Compare LFST & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- DNLI
- Stock Information
- Founded
- LFST 2015
- DNLI 2013
- Country
- LFST United States
- DNLI United States
- Employees
- LFST N/A
- DNLI N/A
- Industry
- LFST Medical/Nursing Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFST Health Care
- DNLI Health Care
- Exchange
- LFST Nasdaq
- DNLI Nasdaq
- Market Cap
- LFST 1.9B
- DNLI 2.1B
- IPO Year
- LFST 2021
- DNLI 2017
- Fundamental
- Price
- LFST $5.17
- DNLI $14.50
- Analyst Decision
- LFST Strong Buy
- DNLI Strong Buy
- Analyst Count
- LFST 5
- DNLI 15
- Target Price
- LFST $8.50
- DNLI $33.85
- AVG Volume (30 Days)
- LFST 2.1M
- DNLI 1.7M
- Earning Date
- LFST 08-07-2025
- DNLI 07-31-2025
- Dividend Yield
- LFST N/A
- DNLI N/A
- EPS Growth
- LFST N/A
- DNLI N/A
- EPS
- LFST N/A
- DNLI N/A
- Revenue
- LFST $1,283,503,000.00
- DNLI N/A
- Revenue This Year
- LFST $15.27
- DNLI N/A
- Revenue Next Year
- LFST $13.94
- DNLI $335.74
- P/E Ratio
- LFST N/A
- DNLI N/A
- Revenue Growth
- LFST 16.31
- DNLI N/A
- 52 Week Low
- LFST $4.76
- DNLI $10.57
- 52 Week High
- LFST $8.61
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- LFST 38.55
- DNLI 48.38
- Support Level
- LFST $4.76
- DNLI $13.83
- Resistance Level
- LFST $5.26
- DNLI $14.66
- Average True Range (ATR)
- LFST 0.19
- DNLI 0.63
- MACD
- LFST 0.02
- DNLI -0.03
- Stochastic Oscillator
- LFST 33.34
- DNLI 31.58
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.